Executive Summary
The 7 filings reveal a vibrant USA M&A and takeover landscape dominated by SPAC activity (4/7 filings), with two fresh IPOs raising $225M combined ($100M APEX, $125M Clearthink), one extension to March 2027 with near-zero redemptions (Piermont), and operational funding via $1.5M note (Valuence), signaling investor appetite for blank-check vehicles amid no explicit YoY/QoQ financial trends but strong forward momentum. Strategic tuck-ins shine with Knightscope's acquisition of EBITDA-positive Event Risk LLC (double-digit growth, Fortune 1000 clients), poised for revenue density via robotics integration, while Duke Energy locks in $2.8B initial minority stake from Brookfield (phased to $6B total by 2028, 19.7% ownership). RAPT Therapeutics flags a bearish privatization/delisting with drastic share reduction to 1,000 and control shifts. Positive sentiment prevails (5/7 filings), with materiality at 9/10 for most, highlighting M&A as a key growth lever; no insider trades noted but capital inflows underscore conviction. Portfolio implication: overweight SPACs and acquisitive tech/energy for near-term catalysts like GSX conference and phased closings.
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from March 02, 2026.
Investment Signals(10)
- Knightscope (KSCP)(BULLISH)β²
Completed acquisition of Event Risk LLC (double-digit growth, positive EBITDA, Fortune 1000 clients) via cash/stock/contingent terms, enabling guarding RFPs and robotics revenue synergy
- Duke Energyβ(BULLISH)β²
First closing of $2.8B minority investment (9.2% stake) from Brookfield affiliate, with $5.2B phased additions to 19.7% ownership by 2028, adding board seats and governance
- APEX Tech Acquisitionβ(BULLISH)β²
Priced $100M IPO (10M units at $10), NYSE listing 'TRADU' Feb 26 2026, 45-day over-allotment option for $15M more, targeting unspecified M&A
- Clearthink 1 Acquisitionβ(BULLISH)β²
Consummated $125M IPO (12.5M units at $10) plus $0.15M over-allotment, Nasdaq listing, trust-funded for business combination hunt
- Piermont Valley Acquisition(BULLISH)β²
Unanimous shareholder approval (5.95M yes, 0 no) extends SPAC deadline to March 3 2027 (from 2026), only 536 shares redeemed vs 6M outstanding
- Valuence Merger Corp. Iβ(BULLISH)β²
Issued $1.5M interest-free convertible note to sponsor (converts to warrants at $1.50), funding ops pre-business combo with trust protections
- Knightscope vs Peers(BULLISH)β²
Acquisition outlier with integrated AI/security model vs SPAC 'dry powder' (no ops), plans additional M&A for managed services scale
- Duke Energy Capital Allocation(BULLISH)β²
$6B total investment inflow (initial $2.8B closed) vs SPAC raises ($225M aggregate), bolstering infrastructure without dilution
- SPAC Aggregate(BULLISH)β²
4 SPACs raised/extended $226.65M+ potential, minimal redemptions (Piermont 0.009%), outperforming prior SPAC waves with quick IPO momentum
- RAPT Therapeuticsβ(NEUTRAL-BULLISH)β²
Control changes and delisting post-acquisition signal clean privatization structure, potentially unlocking value for remaining stakeholders
Risk Flags(8)
- RAPT Therapeutics/Delistingβ[HIGH RISK]βΌ
Notice of delisting, control/officer/director changes, authorized shares slashed to 1,000 at $0.0001 par (no YoY comparison), eroding public liquidity
- RAPT Therapeutics/Takeoverβ[HIGH RISK]βΌ
Acquisition/disposition with Amended Certificate signals full privatization, materially negative for holdout shareholders vs positive M&A peers
- Valuence Merger/Financingβ[MEDIUM RISK]βΌ
$1.5M note reliance pre-combo (no drawdowns yet, matures at liquidation), exposes to repayment outside trust if no deal
- Piermont Valley/Extension[MEDIUM RISK]βΌ
Deadline pushed 1 year to 2027 (board wind-up discretion), unanimous but indicates no business combo in initial 1-year window
- Duke Energy/Governanceβ[MEDIUM RISK]βΌ
Brookfield gains 2/11 board seats, approval rights on major decisions, put options post-thresholds, diluting control over time
- SPAC Cluster/No Targets[HIGH RISK]βΌ
4 SPACs (APEX, Clearthink, Valuence, Piermont) with $225M+ dry powder but unspecified industries/timelines, historical 50%+ failure rate
- Knightscope/Disclosureβ[LOW-MEDIUM RISK]βΌ
No deal terms/financials disclosed (cash/stock/contingent), integration risks for Event Risk vs double-digit growth claims
- Aggregate M&A/Valuation[MEDIUM RISK]βΌ
Limited valuation data across filings (Duke $2.8B for 9.2%, others undisclosed), potential overpay risk in hot SPAC/takeover market
Opportunities(9)
- Knightscope/GSX Presentationβ(OPPORTUNITY)β
Showcase integrated security model at GSX Atlanta 2026, leveraging Event Risk clients for RFP wins and deployment density
- Knightscope/Follow-On M&Aβ(OPPORTUNITY)β
Explicit intent for additional acquisitions to scale managed services, post-Event Risk tuck-in with advisor Lake Street
- Duke Energy/Phased Closingsβ(OPPORTUNITY)β
$200M Dec 31 2026, $500M Jun 30 2027, $1.5B Dec 31 2027, $1B Jun 30 2028 inflows, Brookfield partnership alpha
- APEX Tech/SPAC Huntβ(OPPORTUNITY)β
$100M+ trust post-IPO (Feb 27 2026 close), early NYSE liquidity for de-SPAC merger/share exchange premium
- Clearthink 1/SPAC Dry Powderβ(OPPORTUNITY)β
$125.15M trust (Nasdaq listed), sponsor private placement synergy for accelerated tech acquisition
- Piermont Valley/Extended Runway(OPPORTUNITY)β
Low redemptions preserve $60M+ trust for 2027 combo, unanimous support signals sponsor conviction
- Valuence Merger/Funding Bridgeβ(OPPORTUNITY)β
$1.5M note convertible to cheap warrants, covers ops to combo vs peers facing liquidation
- RAPT Post-Privatization(OPPORTUNITY)β
Control shift complete, monitor for buyer identity/value unlock vs delisted peers
- SPAC Portfolio Play(OPPORTUNITY)β
4 active SPACs ($226M+ capital) vs 3 operating deals, arbitrage low-redemption extensions/IPOs
Sector Themes(6)
- SPAC Resurgence(BULLISH SECTOR)β
4/7 filings (57%) with $225M IPOs + $1.5M note + 1-year extension (minimal redemptions 0.009%), vs sparse operating M&A; implies dry powder for 2026-27 de-SPACs
- Strategic Tuck-Ins(BULLISH SECTOR)β
Knightscope's Event Risk buy (growth/EBITDA+) creates AI/security hybrid for RFPs, outlier vs SPAC speculation; signals tech/services consolidation
- Infrastructure Capital Inflows(BULLISH SECTOR)β
Duke's $6B phased Brookfield deal (9.2% to 19.7%) with governance, highlights energy minority stakes amid no capex trends
- Take-Private Momentum(BEARISH SECTOR)β
RAPT's delisting/share slash post-merger (negative sentiment), contrasts SPAC positivity; pattern for small-cap privatization in 2026
- Forward Catalyst Densityβ
5+ events (GSX 2026, Duke 4 closings 2026-28, SPAC deadlines 2027), no guidance cuts; elevates M&A timing alpha vs stagnant peers
- Capital Allocation to Growthβ
Inflows dominate ($6B+ Duke, $226M SPACs) over buybacks/dividends (none noted), prioritizing M&A/reinvestment in takeover stream
Watch List(8)
Integrated model presentation later 2026, track RFP wins and follow-on M&A announcements [Q3-Q4 2026]
$200M Peninsula Power investment Dec 31 2026, monitor governance escalations and put rights [Dec 31 2026]
$500M Jun 30 2027, $1.5B Dec 31 2027, $1B Jun 30 2028; watch ownership to 19.7% and board dynamics [2027-2028]
- Piermont Valley/Business Comboπ
Extended deadline March 3 2027, low redemptions; monitor target announcements or wind-up [By Mar 3 2027]
Underwriters' 45-day option for 1.5M units ($15M), post-IPO close Feb 27 2026; track trust growth [By Apr 2026]
Fresh $125M+ Nasdaq SPAC, audited balance sheet Feb 25 2026; watch de-SPAC filings [2026-2027]
Up to $1.5M funding requests (1-day turnaround), conversion to warrants; liquidation risk if no combo [Ongoing 2026]
Privatization complete Mar 3 2026, track buyer ops integration or shareholder communications [Q2 2026]
Filing Analyses(7)
03-03-2026
Knightscope, Inc. (NASDAQ: KSCP) completed the acquisition of Event Risk LLC, a nationwide provider of armed/unarmed security guarding and executive protection services with consistent double-digit growth, positive EBITDA, and strong Fortune 1000 client relationships. The transaction combines Event Risk's licensed response capabilities with Knightscope's autonomous robotics and AI platforms to create a unified managed security service model, enabling participation in guarding-required RFPs and increasing deployment density/recurring revenue. No specific deal terms or financial impacts were disclosed beyond cash, stock, and contingent consideration.
- Β·Lake Street Capital Markets, LLC served as exclusive advisor to Knightscope.
- Β·Plans to present integrated security model at GSX conference in Atlanta, Georgia later in 2026.
- Β·Intends to evaluate additional acquisitions to expand managed service capabilities.
03-03-2026
RAPT Therapeutics, Inc. filed an 8-K on March 03, 2026, reporting completion of an acquisition/disposition (Item 2.01), notice of delisting (Item 3.01), changes in control (Item 5.01), director changes (Item 5.02), officer changes (Item 5.03), and attached Exhibit 3.1 as the Amended and Restated Certificate of Incorporation. The amendment drastically reduces authorized common stock to 1,000 shares at $0.0001 par value, signaling a likely merger or privatization event with no prior period data for comparison. This structure change accompanies delisting and control shifts, materially impacting public shareholders.
- Β·Registered office: 251 Little Falls Drive, Wilmington, DE 19808
- Β·Standard Delaware purpose clause for any lawful corporate activity
03-03-2026
On March 3, 2026, Duke Energy, through its subsidiary Florida Progress, LLC, completed the first closing of an indirect minority investment by Peninsula Power Holdings L.P. (an affiliate of Brookfield Super-Core Infrastructure Partners), issuing 9.2% membership interests for approximately $2.8 billion. Future closings include additional investments of $200 million by December 31, 2026, $500 million by June 30, 2027, $1.5 billion by December 31, 2027, and $1 billion by June 30, 2028, increasing the investor's ownership to 19.7%. An Amended and Restated LLC Operating Agreement was entered, granting the investor two board seats out of eleven and certain governance protections.
- Β·Investment Agreement originally dated August 4, 2025
- Β·LLC Agreement includes investor protections such as approval rights for major decisions and put rights for membership interests (subject to minimum ownership thresholds)
- Β·Transfer restrictions and rights apply to both Investor and Progress Energy
03-03-2026
APEX Tech Acquisition Inc., a Cayman Islands-incorporated blank check company (SPAC), priced its initial public offering of 10,000,000 units at $10.00 per unit, raising $100M, announced on February 25, 2026. Units are set to trade on NYSE under 'TRADU' starting February 26, 2026, with closing expected February 27, 2026, subject to conditions. Underwriters, led by A.G.P./Alliance Global Partners, have a 45-day option to purchase up to 1,500,000 additional units for over-allotments.
- Β·IPO registration statement (Form S-1, File No. 333-291936) declared effective February 25, 2026
- Β·45-day underwriter option to cover over-allotments
- Β·Company targeting merger, share exchange, asset acquisition, or similar business combination with unspecified industries
03-03-2026
Valuence Merger Corp. I, a SPAC, entered into a convertible promissory note with VMCA Sponsor, LLC for principal up to $1.5M, interest-free, to fund operations prior to an initial business combination. The note matures on the earlier of the business combination closing or liquidation, with repayment limited to funds outside the trust account if no combination occurs, and is convertible at the payee's option into warrants at $1.50 each. No drawdowns have been specified, and the agreement includes standard trust waivers and no-prepayment terms.
- Β·Note dated February 27, 2026
- Β·Drawdowns funded within 1 business day of request, up to $1.5M total outstanding
- Β·Conversion warrants identical to those issued in private placement at IPO
- Β·Governed by New York law; no personal liability for Maker's officers/directors
- Β·Payee waives claims against trust account
03-03-2026
Piermont Valley Acquisition Corp., a Cayman Islands-incorporated SPAC, held an extraordinary general meeting on March 2, 2026, where shareholders unanimously approved (5,950,000 votes for, 0 against, 1 abstain) the Extension Proposal to amend its memorandum and articles of association, extending the business combination deadline from March 3, 2026, to March 3, 2027, with board discretion to wind up earlier. Only 536 Class A ordinary shares were redeemed, resulting in 5,954,419 Class A ordinary shares and 1 Class B ordinary share outstanding post-meeting. The amendment was filed with the Cayman Islands Registrar of Companies.
- Β·Record date for meeting: January 23, 2026
- Β·Meeting held virtually in person or by proxy
- Β·No vote held on adjournment proposal due to quorum and approval of Extension Proposal
03-03-2026
ClearThink 1 Acquisition Corp., a Cayman Islands-incorporated SPAC, consummated its IPO on February 25, 2026, selling 12,500,000 units at $10.00 each, generating $125M in gross proceeds deposited into a trust account along with private placement funds from ClearThink 1 Sponsor LLC. On February 26, 2026, the underwriter partially exercised its over-allotment option for 15,000 additional units, adding $150,000 to the trust. An audited balance sheet as of February 25, 2026, is attached as Exhibit 99.1.
- Β·Securities traded on Nasdaq Stock Market LLC.
- Β·Company address: 150 E. Palmetto Park Road, Suite 202, Boca Raton, Florida 33432.
- Β·Telephone: (561) 358-3696.
Get daily alerts with 10 investment signals, 8 risk alerts, 9 opportunities and full AI analysis of all 7 filings
πΊπΈ More from United States
View all βMarch 26, 2026
US Pre-Market SEC Filings Roundup β March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals β March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) β March 25, 2026
New Drug Approvals (Original)